Latest Erectile dysfunction Stories
The use of multiple medications is associated with increased severity of erectile dysfunction, according to a Kaiser Permanente study published online in the British Journal of Urology International. This study surveyed 37,712 ethnically diverse men from Southern California and found that men taking various medications are likely to have more severe ED. This was part of the California Men's Health Study, a multiethnic cohort of men ages 46 to 69 who are members of Kaiser Permanente in...
MOUNTAIN VIEW, Calif., Nov. 14, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that new analyses from TA-314, a phase 3 long-term safety and efficacy study of the investigational drug avanafil for the treatment of erectile dysfunction (ED), was presented over the weekend at the 2011 Sexual Medicine Society of North America (SMSNA) Meeting in Las Vegas, NV. Andrew R. McCullough, MD, Professor of Surgery/Urology at Albany Medical College, presented the analysis of results...
MOUNTAIN VIEW, Calif., Nov. 10, 2011 /PRNewswire/ -- Highlights from Avanafil Development Program Include: Early onset of action observed in placebo-controlled trialsComparative in-vitro selectivity of avanafil, sildenafil, vardenafil and tadalafilSafety and efficacy in post-prostatectomy populationVIVUS, Inc. (NASDAQ: VVUS) today announced that multiple abstracts will be presented at the Sexual Medicine Society of North America (SMSNA) on November 12, 2011 in Las Vegas, NV. The SMSNA is...
MALVERN, Pa., Nov. 3, 2011 /PRNewswire/ -- Auxilium Pharmaceuticals, Inc. (Nasdaq: AUXL) today announced the release of clinical practice data from the Testim Registry in the United States (TRiUS). This study showed that daily administration of Testim® 1% (testosterone gel) resulted in significantly improved sexual function and increased total testosterone levels in men with hypogonadism, often referred to as low testosterone. Sexual function assessments from TRiUS, which followed...
MOUNTAIN VIEW, Calif., Nov. 3, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that Timothy Morris, chief financial officer, will present an overview of the company at the Credit Suisse 2011 Healthcare Conference. The VIVUS presentation will take place at the Arizona Biltmore Hotel in Phoenix, AZ on Thursday, November 10, 2011 at 9:30 a.m. MST. A live webcast and 30-day archive of the presentation will be available at http://ir.vivus.com. About...
Advanced Male Medical Center, a medical clinic devoted to the needs of men facing Erectile Dysfunction and Premature Ejaculation, is now offering the HCG diet. San Francisco, CA (PRWEB) October 28, 2011 Advanced Male Medical Center, a San Francisco medical clinic devoted to the needs of men facing erectile dysfunction and premature ejaculation, is now offering the HCG diet. Human Chorionic Gonadotropin (HCG) is a glycoprotein hormone produced in the early stages of pregnancy. This...
PARSIPPANY, N.J., Oct. 21, 2011 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that the U.S. Food and Drug Administration (FDA) approved its Androderm® (testosterone transdermal system) 2 mg and 4 mg formulation. The new smaller size and lower-dose testosterone patch provides highly effective testosterone administration with a 20 percent reduction in the active ingredient from the original strength in a smaller patch size. Watson plans to launch the new...
Renown urologist, Peter Sinaiko, MD FACS, launches new blog to educate patients, medical professionals and regulators about the efficacy of HIFU therapy for treatment of prostate cancer. The blog is located at http://www.hifuprostatecancerdoctor.com. Langhorne, PA (PRWEB) October 20, 2011 Sinako Urology, led by Peter Sinako, MD FACS, announced that it has launched a website and blog dedicated to the coverage of High Intensity Focused Ultrasound or HIFU for the treatment of prostate cancer...
Men's experiences of erectile dysfunction after treatment for colorectal cancer: Qualitative interview study Male bowel cancer patients are very likely to suffer from erectile dysfunction (ED) after treatment and yet the majority are not receiving adequate information about the condition, according to a study published on bmj.com today. Bowel cancer affects over 38,000 people every year in the UK with around half of patients surviving for more than five years after treatment. This...
MOUNTAIN VIEW, Calif., Oct. 14, 2011 /PRNewswire/ -- VIVUS, Inc. (NASDAQ: VVUS) today announced that Timothy Morris, chief financial officer, will present an overview of the company at the 2011 BioCentury NewsMakers in the Biotech Industry Conference. The VIVUS presentation will take place at the Millennium Broadway Hotel in New York, NY on Friday, October 21, 2011 at 10:00 a.m. ET. A live webcast and 30-day archive of the presentation will be available at http://ir.vivus.com. About VIVUS...
